Key Inclusion criteria:

- Adequate performance status, hematologic, renal and liver function.

- Measurable disease per RECIST v1.1

- Cohort 1: Individuals with previously untreated unresectable locally advanced or
metastatic TNBC that are considered PD-L1 negative (as determined by an approved test
according to local regulations).

- Cohort 2: Individuals with unresectable, locally advanced or metastatic TNBC who have
received at least 1 and no more than 2 prior lines of therapy in the unresectable,
locally advanced or metastatic setting. Individuals must have been previously treated
with a taxane in any setting. Individuals with tumors that are considered positive for
PD-L1 expression (as determined by an approved test according to local regulations)
must have received an immune checkpoint inhibitor for a prior-line of treatment for
unresectable locally advanced/metastatic TNBC.

Key Exclusion Criteria:

- Positive serum pregnancy test or breastfeeding female.

- Active CNS disease. Individuals with asymptomatic and stable, treated CNS lesions
(radiation and/or surgery and/or other CNS-directed therapy who have not received
corticosteroids for at least 4 weeks) are allowed.

- RBC transfusion dependence, defined as requiring more than 2 units of packed RBC
transfusions during the 4-week period prior to screening. Red blood cell transfusions
are permitted during the screening period and prior to enrollment to meet the
hemoglobin inclusion criteria.

- History of hemolytic anemia, autoimmune thrombocytopenia, or Evans syndrome in the
last 3 months.

- Prior treatment with CD47 or signal regulatory protein alpha-targeting agents.

- Known inherited or acquired bleeding disorders.

- Cohort 1 only: Disease progression within 6 months following neoadjuvant/adjuvant
therapy.

- Cohort 2 only:

- Individuals with active chronic inflammatory bowel disease (ulcerative colitis,
Crohn disease) and Individuals with a history of bowel obstruction or
gastrointestinal perforation within 6 months of enrollment.

- Individuals who previously received topoisomerase I inhibitors or antibody-drug
conjugates containing a topoisomerase inhibitor.

- High-dose systemic corticosteroids (≥ 20 mg of prednisone or its equivalent) are not
allowed within 2 weeks of Cycle 1 Day 1.

- Have not recovered (ie, ≥ Grade 2 is considered not recovered) from AEs due to a
previously administered agent.

- Note: individuals with any grade neuropathy or alopecia are an exception to
this criterion and will qualify for the study.

- Note: if individuals received major surgery, they must have recovered
adequately from the toxicity and/or complications from the intervention
prior to starting therapy.

Note: Other protocol defined Inclusion/Exclusion criteria may apply.

Eligibility last updated 8/2/23. Questions regarding updates should be directed to the study team contact.